Core Viewpoint - Baoding Traditional Chinese Medicine Hospital is committed to the development of traditional Chinese medicine, focusing on improving medical services, regional collaboration, and cultural dissemination, achieving significant results in public health benefits since the 14th Five-Year Plan [1][2]. Group 1: Medical Service Improvement - The hospital aims to enhance its traditional Chinese medicine service capabilities, establishing a national-level specialty in endocrinology and several provincial-level specialties, including rehabilitation, nephrology, geriatrics, cardiology, ophthalmology, and preventive medicine [1]. - The hospital optimized 30 traditional Chinese medicine diagnosis and treatment plans, 29 clinical pathways, and promoted 75 suitable traditional Chinese medicine techniques and 30 nursing techniques, leading to a 122.31% increase in outpatient visits compared to 2020 [1]. Group 2: Collaborative Development - The hospital became a member of the closely-knit medical alliance of the China Rehabilitation Research Center, resulting in a 538.52% increase in rehabilitation medical income, a 381.46% increase in outpatient visits, and a 149.09% increase in inpatient visits [2]. - Collaborations with Beijing University of Chinese Medicine and Capital Medical University have been established for talent cultivation and specialty alliances, creating a diabetes management model that integrates traditional and Western medicine [2]. Group 3: Cultural Dissemination - The hospital has developed multiple academic dissemination platforms, including the Shouzhentang, Shouzhenshu Academy, and Shouzhentang Traditional Chinese Medicine Museum, and has conducted over 200 public welfare activities related to traditional Chinese medicine culture [2]. - The hospital has launched 36 unique media programs, attracting over 130,000 followers, and has registered the "Shouzheng" trademark in Hong Kong, promoting its brand internationally [2].

Core Points - The company has issued a special report on the use of raised funds as of June 30, 2025, ensuring the information is true, accurate, and complete [1] - The company raised a total of RMB 276 million through the issuance of convertible bonds in March 2022 and RMB 301.99 million through a private placement of A-shares in September 2023 [2][5] - The company has established a fund management system to ensure the effective use of raised funds and protect investor rights [2][3] Fundraising Overview - The total amount raised from the convertible bonds was RMB 276 million, with a net amount of RMB 272 million after deducting issuance costs [1] - The total amount raised from the A-share issuance was RMB 301.99 million, with a net amount of RMB 294.84 million after deducting issuance costs [2] - As of June 30, 2025, the company has used a total of RMB 421.71 million of the raised funds, with RMB 155.79 million remaining [5][6] Fund Management and Usage - The company has implemented a dedicated account management system for the raised funds, ensuring compliance with relevant laws and regulations [2][3] - As of June 30, 2025, several fundraising accounts have been closed, and the remaining funds are stored in dedicated accounts [3][4] - The company has not engaged in any temporary use of idle funds for working capital or cash management [5][6] Project Updates and Changes - The "Construction Project of Centralized Preparation Center for Medical Institutions in Shaanxi Province" has been delayed and the completion date has been extended to December 31, 2024, due to various factors [6][9] - The company has decided to terminate the project and use the remaining funds for permanent working capital, following board and supervisory approvals [6][9] - The company has also terminated the "Quality Inspection and Testing Shared Platform Upgrade Project" and redirected the remaining funds to working capital [6][9] Compliance and Disclosure - The company has ensured that all fundraising activities and fund usage have been disclosed in a timely, truthful, accurate, and complete manner [5][6] - There have been no violations in the management of raised funds during the reporting period [5][6]